A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Latest Information Update: 13 Jun 2022
At a glance
- Drugs Itepekimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 16 May 2022 Status changed from completed to discontinued.
- 04 Apr 2022 This trial has been discontinued in Japan, according to Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 22 Sep 2020 This trial has been Discontinued in united kingdom, according to European Clinical Trials Database record.